Insulet (PODD, Health Care Equipment) Stock Valuation & Fair Value Mixed on our tests
Insulet (PODD, Health Care Equipment) trades at a blended P/E of 21.5, a multiple its historical normal P/E is too distorted to compare with, with a forward growth estimate of 19.5% and a PEG of 1.10.
The historical normal P/E published for Insulet is 278.2, more than six times its current multiple. A gap that wide comes from the company's earnings history rather than from its price, so this page quotes no premium or discount against it.
- Price $134.47 at the 2026-10-08 close, 1.1% below the 20-day average ($135.91) and 5.8% below the 50-day ($142.69).
- RSI (14) at 42.8.
- 52-week range $130.47 to $346.36: the price is 61.2% below the high and 3.1% above the low.
The Street vs SeerForecast
Wall Street's mean price target for PODD is $171.91 across 22 analysts, 27.8% above the current price. The average analyst rating is Buy. Our SeerForecast read of the same stock, formed without analyst targets: mixed on our tests. When the two disagree, start your digging there.
Valuation flags
- Misses analyst estimates often (55%)
Verdict history
tickerseer's rating moved from favorable on our tests (2026-06-03) to mixed on our tests (2026-10-05). New rating rules took effect in the week of 2026-09-28, and this rating moved across that change, so part of the move may come from the new rules rather than the company.
Not every point was recorded live. Points marked recalculated apply today's valuation rules to the metrics tickerseer archived that week.
Selected weeks: the first, the latest, every week the rating moved, and the cheapest and dearest.
Show all 37 weeks
Frequently asked questions
Is Insulet stock overvalued?
Insulet trades at a blended P/E of 21.5, with a PEG of 1.10 on 19.5% forward growth. Its published historical normal P/E is 278.2, more than six times that, so there is no meaningful premium or discount to quote. tickerseer currently rates it mixed on our tests.
What is Insulet's fair value and PEG?
Insulet trades at a blended P/E of 21.5, a PEG of 1.10, and a forward growth estimate of 19.5%.
Has tickerseer's rating of Insulet changed?
tickerseer's rating moved from favorable on our tests (2026-06-03) to mixed on our tests (2026-10-05). New rating rules took effect in the week of 2026-09-28, and this rating moved across that change, so part of the move may come from the new rules rather than the company.
What is the analyst price target for Insulet?
The mean Wall Street price target for Insulet is $171.91 across 22 analysts, 27.8% above the current price. tickerseer's SeerForecast verdict is formed independently of analyst targets.
Industry: Health Care Equipment. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.
Get the free weekly earnings preview
One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.
It's free, and you can unsubscribe any time. We also send a short product update once a month. Educational content, not investment advice.